比利时资助了Gentflow对脂肪肝的基因治疗,预期会进行人类试验。 Belgium funds Genflow’s gene therapy for fatty liver, with human trials expected.

为了推进其主要基因疗法候选者GF-1002的研发,Genflow Biosciences PLC已从比利时瓦隆地区的400万欧元非稀释性资助中获得336,467欧元,用于治疗代谢功能障碍相关的脂肪肝炎 (MASH). Genflow Biosciences PLC has received €336,467 from a €4 million non-dilutive grant by Belgium’s Wallonia Region to advance its lead gene therapy candidate, GF-1002, for treating metabolic dysfunction-associated steatohepatitis (MASH). 该疗法提供了SIRT6基因的百年变种,目前正在对老狗进行测试,临时结果显示生存、安全有所改善,肌肉质量和生活质量呈积极趋势。 The therapy delivers a centenarian variant of the SIRT6 gene and is being tested in aging dogs, with interim results showing improved survival, safety, and positive trends in muscle mass and quality of life. 预计将根据里程碑的成就提供额外资金。 Additional funding is expected based on milestone achievements. 预计将对MASH进行人类临床试验。 A human clinical trial for MASH is anticipated.